Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy G, Ignatius Ou SH, Stephens PJ, McPherson J, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770-6. doi: 10.1016/j.jtho.2018.06.019. [Epub ahead of print]

PMID:
29981927
2.

Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA.

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D.

J Mol Diagn. 2018 Jun 22. pii: S1525-1578(17)30527-5. doi: 10.1016/j.jmoldx.2018.05.004. [Epub ahead of print]

3.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

4.

Adolescents Spending Time Alone With Pediatricians During Routine Visits: Perspectives of Parents in a Primary Care Clinic.

Miller VA, Friedrich E, García-España JF, Mirman JH, Ford CA.

J Adolesc Health. 2018 Jun 7. pii: S1054-139X(18)30064-8. doi: 10.1016/j.jadohealth.2018.01.014. [Epub ahead of print]

PMID:
29887486
5.

Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ignatius Ou SH.

J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30674-9. doi: 10.1016/j.jtho.2018.05.027. [Epub ahead of print]

6.

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.

Parikh AR, Ali SM, Schrock AB, Albacker LA, Miller VA, Stephens PJ, Crilley P, Markman M.

Lung Cancer (Auckl). 2018 May 18;9:45-47. doi: 10.2147/LCTT.S161738. eCollection 2018.

7.

Decision-Making Involvement and Prediction of Adherence in Youth With Type 1 Diabetes: A Cohort Sequential Study.

Miller VA, Jawad AF.

J Pediatr Psychol. 2018 May 17. doi: 10.1093/jpepsy/jsy032. [Epub ahead of print]

PMID:
29788441
8.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
9.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
10.

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA.

Leukemia. 2018 Mar 23. doi: 10.1038/s41375-018-0108-y. [Epub ahead of print]

PMID:
29654269
11.

Changes in Parental Hopes for Seriously Ill Children.

Hill DL, Nathanson PG, Carroll KW, Schall TE, Miller VA, Feudtner C.

Pediatrics. 2018 Apr;141(4). pii: e20173549. doi: 10.1542/peds.2017-3549.

PMID:
29567813
12.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

Suh JH, Schrock AB, Johnson A, Lipson D, Gay LM, Ramkissoon S, Vergilio JA, Elvin JA, Shakir A, Ruehlman P, Reckamp KL, Ou SI, Ross JS, Stephens PJ, Miller VA, Ali SM.

Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493. doi: 10.1634/theoncologist.2017-0493. [Epub ahead of print]

PMID:
29540602
13.

Optimizing Children's Involvement in Decision Making Requires Moving Beyond the Concept of Ability.

Miller VA.

Am J Bioeth. 2018 Mar;18(3):20-22. doi: 10.1080/15265161.2017.1418923. No abstract available.

PMID:
29466131
14.

Controller adherence following hospital discharge in high risk children: A pilot randomized trial of text message reminders.

Kenyon CC, Gruschow SM, Quarshie WO, Griffis H, Leach MC, Zorc JJ, Bryant-Stephens TC, Miller VA, Feudtner C.

J Asthma. 2018 Feb 13:1-9. doi: 10.1080/02770903.2018.1424195. [Epub ahead of print]

PMID:
29437489
15.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. eCollection 2018 Feb.

16.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

PMID:
29373100
17.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.

PMID:
29370427
18.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

PMID:
29363525
19.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.

20.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21. No abstract available.

PMID:
29325860
21.

PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors.

Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R, Miller VA, Cantley LC, Meiler J, Arteaga CL.

Clin Cancer Res. 2018 Mar 15;24(6):1426-1435. doi: 10.1158/1078-0432.CCR-17-2141. Epub 2017 Dec 28.

PMID:
29284706
22.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16.

23.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM.

Lung Cancer. 2017 Nov;113:51-58. doi: 10.1016/j.lungcan.2017.08.014. Epub 2017 Aug 31.

24.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM.

Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27.

PMID:
29079636
25.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

Lee H, El Jabbour T, Ainechi S, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Ali SM, Schrock A, Fabrizio D, Frampton G, Nazeer T, Miller VA, Stephens PJ, Ross JS.

Hum Pathol. 2017 Dec;70:84-91. doi: 10.1016/j.humpath.2017.10.007. Epub 2017 Oct 24.

PMID:
29079173
26.

Effect of Financial Incentives on Glucose Monitoring Adherence and Glycemic Control Among Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial.

Wong CA, Miller VA, Murphy K, Small D, Ford CA, Willi SM, Feingold J, Morris A, Ha YP, Zhu J, Wang W, Patel MS.

JAMA Pediatr. 2017 Dec 1;171(12):1176-1183. doi: 10.1001/jamapediatrics.2017.3233.

PMID:
29059263
27.

Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.

Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ.

Clin Genitourin Cancer. 2018 Apr;16(2):e373-e382. doi: 10.1016/j.clgc.2017.09.001. Epub 2017 Sep 7.

PMID:
28974397
28.

How do providers discuss the results of pediatric exome sequencing with families?

Walser SA, Werner-Lin A, Mueller R, Miller VA, Biswas S, Bernhardt BA.

Per Med. 2017 Sep;14(5):409-422. doi: 10.2217/pme-2017-0015. Epub 2017 Sep 4.

29.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

PMID:
28945887
30.

Attitudes and Beliefs Pertaining to Sexual and Reproductive Health Among Unmarried, Female Bhutanese Refugee Youth in Philadelphia.

Dhar CP, Kaflay D, Dowshen N, Miller VA, Ginsburg KR, Barg FK, Yun K.

J Adolesc Health. 2017 Dec;61(6):791-794. doi: 10.1016/j.jadohealth.2017.06.011. Epub 2017 Sep 19.

31.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.

Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB.

Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.

32.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993.

33.

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK.

Eur Urol Focus. 2016 Jun;2(2):204-209. doi: 10.1016/j.euf.2015.11.007. Epub 2015 Dec 9.

PMID:
28723536
34.

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

Schrock AB, Lai A, Ali SM, Miller VA, Raez LE.

J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017. No abstract available.

35.

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM.

Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12.

36.

Genomic Profiling of Small-Bowel Adenocarcinoma.

Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ.

JAMA Oncol. 2017 Nov 1;3(11):1546-1553. doi: 10.1001/jamaoncol.2017.1051.

PMID:
28617917
37.

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.

Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH.

Eur Urol. 2018 Jan;73(1):71-78. doi: 10.1016/j.eururo.2017.05.033. Epub 2017 Jun 4.

PMID:
28592388
38.

Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.

Ali SM, Yao M, Yao J, Wang J, Cheng Y, Schrock AB, Chirn GW, Chen H, Mu S, Gay L, Elvin JA, Suh J, Miller VA, Stephens PJ, Ross JS, Wang K.

Cancer. 2017 Sep 15;123(18):3628-3637. doi: 10.1002/cncr.30781. Epub 2017 Jun 5.

PMID:
28581676
39.

Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.

Heilmann AM, Schrock AB, He J, Nahas M, Curran K, Shukla N, Cramer S, Draper L, Verma A, Erlich R, Ross J, Stephens P, Miller VA, Ali SM, Verglio JA, Tallman MS, Mughal TI.

Leukemia. 2017 Sep;31(9):1989-1992. doi: 10.1038/leu.2017.161. Epub 2017 May 29. No abstract available.

PMID:
28552906
40.

Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.

Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, Keech J Jr, Chmielecki J.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a000778. doi: 10.1101/mcs.a000778. Print 2017 Sep.

41.

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.

Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK.

Oncologist. 2017 Jul;22(7):768-773. doi: 10.1634/theoncologist.2017-0054. Epub 2017 May 15.

42.

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.

Lai AZ, Schrock AB, Erlich RL, Ross JS, Miller VA, Yakirevich E, Ali SM, Braiteh F.

Oncologist. 2017 Jul;22(7):774-779. doi: 10.1634/theoncologist.2016-0376. Epub 2017 May 15.

43.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):e155-e157. doi: 10.1016/j.jtho.2017.04.023. Epub 2017 May 9. No abstract available.

PMID:
28499860
44.

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.

Gay LM, Kim S, Fedorchak K, Kundranda M, Odia Y, Nangia C, Battiste J, Colon-Otero G, Powell S, Russell J, Elvin JA, Vergilio JA, Suh J, Ali SM, Stephens PJ, Miller VA, Ross JS.

Oncologist. 2017 Jul;22(7):834-842. doi: 10.1634/theoncologist.2016-0287. Epub 2017 May 11.

45.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.

Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V.

Oncotarget. 2017 Jun 13;8(24):39254-39267. doi: 10.18632/oncotarget.16845.

46.

Children's Decision-Making Involvement About Research Participation: Associations With Perceived Fairness and Self-Efficacy.

Miller VA, Feudtner C, Jawad AF.

J Empir Res Hum Res Ethics. 2017 Apr;12(2):87-96. doi: 10.1177/1556264617696921. Epub 2017 Mar 14.

47.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM.

Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.

48.

Mechanism of plasmin generation by S100A10.

Miller VA, Madureira PA, Kamaludin AA, Komar J, Sharma V, Sahni G, Thelwell C, Longstaff C, Waisman DM.

Thromb Haemost. 2017 Jun 2;117(6):1058-1071. doi: 10.1160/TH16-12-0936. Epub 2017 Apr 6.

PMID:
28382372
49.

Automated Adherence Reminders for High Risk Children With Asthma: A Research Protocol.

Adams SA, Leach MC, Feudtner C, Miller VA, Kenyon CC.

JMIR Res Protoc. 2017 Mar 27;6(3):e48. doi: 10.2196/resprot.6674.

50.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.

J Thorac Oncol. 2017 Jun;12(6):932-942. doi: 10.1016/j.jtho.2017.03.005. Epub 2017 Mar 16.

Supplemental Content

Loading ...
Support Center